Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Invasive Bladder Cancer × Clear all

Phase

Phase NA 3 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2422 Carcinoma, Non-Small-Cell Lung 1969 Prostatic Neoplasms 1275 Colorectal Neoplasms 1132 Neoplasms 1085 Multiple Myeloma 938 Lung Neoplasms 921 Neoplasm Metastasis 883 Leukemia, Myeloid, Acute 851 Lymphoma 785 Melanoma 766 Pancreatic Neoplasms 722 Ovarian Neoplasms 702 Carcinoma, Hepatocellular 678 Stomach Neoplasms 667 Recurrence 662 Leukemia 647 Lymphoma, Non-Hodgkin 602 Leukemia, Lymphocytic, Chronic, B-Cell 576 Squamous Cell Carcinoma of Head and Neck 542 Lymphoma, Large B-Cell, Diffuse 542 Brain Neoplasms 527 Head and Neck Neoplasms 523 Precursor Cell Lymphoblastic Leukemia-Lymphoma 521 Glioblastoma 514 Carcinoma, Renal Cell 506 Rectal Neoplasms 495 Sarcoma 455 Myelodysplastic Syndromes 455 Lymphoma, Follicular 447

Interventions

tremelimumab 1 durvalumab 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡